CNC
CENTENE CORPEvidence as of 2026-09-02Overview · CENTENE CORP
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. It operates in two segments, Managed Care and Specialty Services. The Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's he…
Management team
- Ms. Katie Nicole Casso · Senior VP, Chief Accounting Officer & Corporate ControllerFind on LinkedIn
- Ms. Susan R. Smith · Chief Operating OfficerFind on LinkedIn
- Mr. David P. Thomas · CEO of Markets & MedicaidFind on LinkedIn
- Mr. Christopher Andrew Koster · Executive VP, General Counsel & SecretaryFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
−0.1 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed ( -0.1 of a possible +2; was -0.1 before debate) · confidence high. Reported GAAP revenue rose from $ 46,620,000,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $ 53,579,000,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo). Gross profit in absolute terms moved from $ 5,288,000,000 in the fiscal Q1 2025 to $ 4,617,000,000 in the fiscal Q2 2026, with computed gross margins of ~ 11.3 % and ~ 8.6 % respectively, showing margin compression versus the Q1 2025 level but a recovery relative to some intervening quarters.
Operating income and net income were volatile over the sequence of filings: operating income (loss) was - $ 6,958,700,000 in the fiscal Q3 2025 (2025-07-01 to 2025-09-30, 3mo), recovered to $ 1,861,000,000 in the fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo), and declined to $ 1,198,000,000 in the fiscal Q2 2026. Net income followed a similar pattern: - $ 6,631,000,000 in the fiscal Q3 2025, $ 1,541,000,000 in the fiscal Q1 2026, and $ 1,091,000,000 in the fiscal Q2 2026. Trailing twelve‑month free cash flow is $ 8,978,000,000 (free cash flow per share $ 18.0413) and price to trailing twelve‑month free cash flow is 3.62, while trailing twelve‑month EPS is - $ 8.71 and EV/EBITDA is not reported because trailing EBITDA is negative $ 3,106,000,000.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Reported GAAP revenues rose from $46,620,000,000 in the fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $53,579,000,000 in the fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0001071739-26-000098Gross profit (absolute) moved from $5,288,000,000 in fiscal Q1 2025 (2025-01-01 to 2025-03-31, 3mo) to $4,617,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo); computed gross margin was ~11.3% in fiscal Q1 2025 (5,288 / 46,620) and ~8.6% in fiscal Q2 2026 (4,617 / 53,579), showing margin compression versus the Q1 2025 level but higher than some intervening quarters.
XBRL companyfacts · 0001071739-25-000086Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
On August 12, 2026, Andrew Asher informed the company that he intends to retire as Chief Financial Officer effective December 31, 2026, and that thereafter he will serve as Strategic Advisor reporting to the CEO through the end of 2027.
8-K filed 2026-08-17The company announced on August 17, 2026 that it identified Christopher Neczypor as Mr. Asher’s successor, with Neczypor expected to become Chief Financial Officer effective January 1, 2027 and to begin serving as Executive Vice President on or about September 1, 2026.
8-K filed 2026-08-17Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum over the trailing 12-1 months is +144.6% and the cross-sectional rank is the 96th percentile of the 547-stock research universe.
Moneyta signal set · 2026-09-01weakened in debateMomentum over the trailing 6 months is +48.9% and the cross-sectional rank is the 93th percentile of the 547-stock research universe.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Ensign Peak Advisors, Inc. is reported as the only 13F institutional holder with a position value of $8.8M in the 13F portfolio reported for the period ended 2026-03-31; the institutional holdings value changed -22.3% quarter-over-quarter and the filing shows one exited position and a holder count decrease of 1.
13F holdings · 1 filers · as of 2026-03-31As of 2026-09-02, CNC appears as a constituent in multiple large ETFs with small fund weights: XLV at 0.55%, VO at 0.37%, VTV at 0.14%, VOO at 0.06%, SCHX at 0.05%, SCHB at 0.05%, and IVV at 0.05%.
ETF constituents · market dataReads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets ran pieces focused on a "Marketplace recovery" theme suggesting improving profitability dynamics for Centene driven by pricing, medical cost trends and risk dynamics.
News · finance.yahoo.com · 2026-09-01At least two independent commentary pieces describe Centene's stock as still attractive or 'cheap' on valuation metrics despite a large prior price run.
News · kalkinemedia.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Two sales by an officer/insider total $6.9M for 104,103 shares in the 180-day window.
Form 4 · KOSTER CHRISTOPHER (Secretary & General Counsel) · $3.1M sold · 2026-08-18KOSTER CHRISTOPHER (Secretary & General Counsel) sold 47,603 shares for "$3.1M" on 2026-08-18 as reported in the Form 4 filing.
Form 4 · KOSTER CHRISTOPHER (Secretary & General Counsel) · $3.1M sold · 2026-08-18Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-derived implied free-cash-flow growth rate that today's price would justify is -27.85% per year.
Valuation inputs · SEC XBRL + stored EOD closePrice to trailing twelve month free cash flow is 3.62.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
Several claims jointly support a favorable read: reported GAAP revenue growth from $46.6B to $53.6B (fundamentals-0) and multiple positive market signals (market-0, market-1, market-2) provide strong, contemporaneous evidence of improving top-line momentum and strong price momentum. Valuation and liquidity metrics (valuation-1, valuation-2, valuation-5) provide corroborating strength: very low TTM price/FCF, substantial reported cash exceeding long-term debt, and sizable TTM free cash flow suggest the company generates meaningful cash despite accounting-level noise. Company-specific news items and corporate moves (news-0, news-1, news-3, news-4, filings-1/3) add medium-strength evidence of improving marketplace dynamics, positive narrative coverage, and management continuity/staffing that market observers often view positively. The strength of the revenue, cash-flow and price-momentum signals is high (direct, recent reported figures and market signal calculations); other signals (operating volatility, insider sales, negative EBITDA/EPS) are factual but represent weaker counterpoints when weighed against strong free cash flow and cash liquidity.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.33
35 surviving claims rest on 16 distinct sources; the heaviest analyst carries 17% of them, and 97% of what the desk raised survived the debate.
The surviving read is supported by multiple claims but relies on a relatively small set of distinct sources and a single analyst carries a noticeable share of the load, so the overall read can be informative but is somewhat brittle to source-level errors or analyst revision. The very high debate-survival rate means the desk’s assertions passed internal challenge, yet users should treat weight given to any single source or analyst as limited — corroboration from additional, independent evidence would increase confidence.
Peer context · computed, not argued
12-1 momentum ranks 1st of 4 in Healthcare Plans (as of 2026-09-01).
90-day volatility ranks 1st of 4 in Healthcare Plans (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
14 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+0.2 to the score
4 documents· 2 cited
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.3 to the score
3 holdings records· 2 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
2 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−0.6 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on CNC Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.